Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

BACKGROUND: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. However, because breast cancer is a highly heterogeneous disease, the responses of different patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Zongbi, Ma, Fei, Liu, Binliang, Guan, Xiuwen, Li, Lixi, Li, Chunxiao, Qian, Haili, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515626/
https://www.ncbi.nlm.nih.gov/pubmed/31088410
http://dx.doi.org/10.1186/s12885-019-5668-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515626/
https://www.ncbi.nlm.nih.gov/pubmed/31088410
http://dx.doi.org/10.1186/s12885-019-5668-3

Ejemplares similares